Targeted therapies in leukemia

Organisational unit: Research group

Research areas and keywords

UKÄ subject classification

  • Cancer and Oncology


  • Leukemia, AML, stem cells, antibody, targeted therapy


Acute myeloid leukemia (AML) is a fatal disorder of the blood-forming bone marrow cells. In most patients, the cellular origin of AML is thought to be a normal hematopoietic stem cell (HSC) that through a series of genetic lesions gives rise to cells with leukemia-initiating capacity, also termed leukemia stem cells (LSCs), which propagate into frank AML. The major goals of our research is to identify therapeutic targets essential for LSCs, to generate novel insights into LSC biology, and to provide in vivo proof of concept for a therapeutic effect. To this end, we use pooled CRISPR/Cas9-screens and lentiviral barcoding of LSC. We have a translational focus and our research has already resulted in a spin-off company (Cantargia). If successful, our research may translate into new therapeutic opportunities in AML, a disease associated with poor prognosis.

Recent research outputs

Mia Eriksson 2018 Lund: Lund University, Faculty of Medicine. 69 p.

Research output: ThesisDoctoral Thesis (compilation)

Elsa Arbajian, Puls, F., Antonescu, C. R., Amary, F. M., Sciot, R., Debiec-Rychter, M., Sumathi, V., Marcus Järås, Magnusson, L., Nilsson, J., Jakob Hofvander & Fredrik Mertens 2017 Dec In : Clinical Cancer Research. 23, 23, p. 7426-7434

Research output: Contribution to journalArticle

Helena Ågerstam, Hansen, N., Sofia von Palffy, Carl Sandén, Reckzeh, K., Christine Karlsson, Lilljebjörn, H., Niklas Landberg, Maria Askmyr, Högberg, C., Rissler, M., Porkka, K., Wadenvik, H., Mustjoki, S., Johan Richter, Marcus Järås & Thoas Fioretos 2016 Dec 8 In : Blood. 128, 23, p. 2683-2693

Research output: Contribution to journalArticle

View All (8)